Precision BioSciences Schedule 13G/A shows that Readout-affiliated entities and Matthew Smith reported collective beneficial ownership of up to 1,119,311 shares of the issuer's common stock as of June 30, 2025, representing approximately 9.4% of the outstanding class. The filing breaks ownership across Readout Capital, Readout Capital GP, ROC Holdings SPV II, Readout Holdings GP and Matthew Smith, and discloses that ROC SPV II directly held 686,437 shares plus warrants exercisable into 220,000 shares. Readout Capital also manages a separate account holding 200,000 shares under an investment management agreement. Signatures certify the disclosures.
Positive
Clear ownership disclosure with specific share counts and voting/dispositive-power breakdowns for each reporting person
Inclusion of warrants (220,000 exercisable shares) is explicitly disclosed, clarifying potential future dilution and voting power
Negative
None.
Insights
TL;DR Readout group and Matthew Smith disclosed meaningful minority positions (~7.6%–9.4%), including warrants, without seeking control.
The Schedule 13G/A reports that as of June 30, 2025 the combined positions include 686,437 directly held shares by ROC SPV II, 220,000 shares issuable upon exercise of warrants, and a managed-account position of 200,000 shares, producing aggregated beneficial ownership figures of 7.6%–9.4% across reporting persons based on 11,636,981 shares outstanding plus exercisable warrants. The filing states the securities were not acquired to influence control and provides voting/dispositive-power breakdowns. Impact to trading depends on market reaction to a disclosed sizable passive stake and potential warrant exercises.
TL;DR Governance disclosure is complete: ownership, voting/dispositive power, and certifying signatures are provided.
The filing identifies the reporting entities, their Delaware organization, address, and the chain of control: Readout Capital as investment manager, Readout Capital GP and Readout Holdings GP as general partners, and Matthew Smith as manager. It quantifies sole and shared voting and dispositive powers and explicitly states the holdings were not acquired to change control, consistent with Schedule 13G treatment. From a governance perspective, this clarifies who may influence shareholder votes and the presence of warrants that could increase economic exposure.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
PRECISION BIOSCIENCES INC
(Name of Issuer)
Common Stock, par value $0.000005 per share
(Title of Class of Securities)
74019P207
(CUSIP Number)
06/30/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
74019P207
1
Names of Reporting Persons
Readout Capital, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
200,000.00
6
Shared Voting Power
906,437.00
7
Sole Dispositive Power
200,000.00
8
Shared Dispositive Power
906,437.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,106,437.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.3 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
74019P207
1
Names of Reporting Persons
Readout Capital GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
200,000.00
6
Shared Voting Power
906,437.00
7
Sole Dispositive Power
200,000.00
8
Shared Dispositive Power
906,437.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,106,437.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP No.
74019P207
1
Names of Reporting Persons
ROC Holdings SPV II, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
906,437.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
906,437.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
906,437.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.6 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
74019P207
1
Names of Reporting Persons
Readout Holdings GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
906,437.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
906,437.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
906,437.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.6 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP No.
74019P207
1
Names of Reporting Persons
Matthew Smith
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
212,874.00
6
Shared Voting Power
906,437.00
7
Sole Dispositive Power
212,874.00
8
Shared Dispositive Power
906,437.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,119,311.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
PRECISION BIOSCIENCES INC
(b)
Address of issuer's principal executive offices:
302 East Pettigrew St., Suite A-100, Durham, North Carolina, 27701
Item 2.
(a)
Name of person filing:
(i) Readout Capital, LP, (ii) Readout Capital GP, LLC, (iii) ROC Holdings SPV II, LP, (iv) Readout Holdings GP, LLC, and (v) Matthew Smith (collectively, the "Reporting Persons")
(b)
Address or principal business office or, if none, residence:
For each of the Reporting Persons: 1630 Columbia Road NW, Unit 418, Washington, D.C. 20009
(c)
Citizenship:
(i) Readout Capital, LP is a Delaware limited partnership, (ii) Readout Capital GP, LLC is a Delaware limited liability company, (iii) ROC Holdings SPV II, LP is a Delaware limited partnership, (iv) Readout Holdings GP, LLC is a Delaware limited liability company and (v) Matthew Smith is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.000005 per share
(e)
CUSIP No.:
74019P207
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information in Item 9 of the cover pages of this Schedule 13G for each of the Reporting Persons, which is as June 30, 2025, is incorporated herein by reference. As of June 30, 2025, ROC Holdings SPV II, LP ("ROC SPV II") directly held 686,437 shares of Common Stock, par value $0.000005 per share ("Common Stock"), of Precision BioSciences, Inc. (the "Issuer") and warrants exercisable for 220,000 shares of Common Stock of the Issuer. Readout Holdings GP, LLC ("Readout Holdings GP") is the general partner of ROC SPV II and Readout Capital, LP ("Readout Capital") serves as investment manager for ROC SPV II. Readout Capital GP, LLC ("Readout Capital GP") is the general partner of Readout Capital and Matthew Smith is the Manager of each of Readout Holdings GP and Readout Capital GP. In addition, Readout Capital serves as the investment manager for a managed account that as of June 30, 2025, held 200,000 shares of Common Stock of the Issuer, and Readout Capital has been delegated voting and investment power over shares of Common Stock held by such managed account pursuant to an Investment Management Agreement. As of June 30, 2025, Matthew Smith directly held 12,874 shares of Common Stock of the Issuer.
(b)
Percent of class:
As of June 30, 2025, each of Readout Capital and Readout Capital GP may have been deemed to have beneficially owned 9.3% of the shares of Common Stock of the Issuer outstanding. As of June 30, 2025, each of ROC SPV II and Readout Holdings GP may have been deemed to have beneficially owned 7.6% of the shares of Common Stock of the Issuer outstanding. As of June 30, 2025, Matthew Smith may have been deemed to have beneficially owned 9.4% of the shares of Common Stock of the Issuer outstanding. Such percentages are based on 11,636,981 shares of Common Stock of the Issuer outstanding as of June 30, 2025, as disclosed in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 7, 2025, plus 220,000 shares of Common Stock issuable upon exercise of warrants directly held by ROC SPV II as of June 30, 2025.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
As of June 30, 2025, each of Readout Capital and Readout Capital GP may have been deemed to have had sole power to vote or to direct the vote of 200,000 shares of Common Stock. As of June 30, 2025, each of ROC SPV II and Readout Holdings GP may have been deemed to have had sole power to vote or direct the vote of 0 shares of Common Stock. As of June 30, 2025, Matthew Smith may have been deemed to have had sole power to vote or to direct the vote of 212,874 shares of Common Stock.
(ii) Shared power to vote or to direct the vote:
As of June 30, 2025, each of Readout Capital and Readout Capital GP may have been deemed to have had shared power to vote or to direct the vote of 906,437 shares of Common Stock, which amount includes 220,000 shares of Common Stock issuable upon exercise of warrants directly held by ROC SPV II as of June 30, 2025. As of June 30, 2025, each of ROC SPV II and Readout Holdings GP may have been deemed to have had shared power to vote or direct the vote of 906,437 shares of Common Stock, which amount includes 220,000 shares of Common Stock issuable upon exercise of warrants directly held by ROC SPV II as of June 30, 2025. As of June 30, 2025, Matthew Smith may have been deemed to have had shared power to vote or to direct the vote of 906,437 shares of Common Stock, which amount includes 220,000 shares of Common Stock issuable upon exercise of warrants directly held by ROC SPV II as of June 30, 2025.
(iii) Sole power to dispose or to direct the disposition of:
As of June 30, 2025, each of Readout Capital and Readout Capital GP may have been deemed to have had sole power to dispose or to direct the disposition of 200,000 shares of Common Stock. As of June 30, 2025, each of ROC SPV II and Readout Holdings GP may have been deemed to have had sole power to dispose or direct the disposition of 0 shares of Common Stock. As of June 30, 2025, Matthew Smith may have been deemed to have had sole power to dispose or to direct the disposition of 212,874 shares of Common Stock.
(iv) Shared power to dispose or to direct the disposition of:
As of June 30, 2025, each of Readout Capital and Readout Capital GP may have been deemed to have had shared power to dispose or to direct the disposition of 906,437 shares of Common Stock, which amount includes 220,000 shares of Common Stock issuable upon exercise of warrants directly held by ROC SPV II as of June 30, 2025. As of June 30, 2025, each of ROC SPV II and Readout Holdings GP may have been deemed to have had shared power to dispose or direct the disposition of 906,437 shares of Common Stock, which amount includes 220,000 shares of Common Stock issuable upon exercise of warrants directly held by ROC SPV II as of June 30, 2025. As of June 30, 2025, Matthew Smith may have been deemed to have had shared power to dispose or to direct the disposition of 906,437 shares of Common Stock, which amount includes 220,000 shares of Common Stock issuable upon exercise of warrants directly held by ROC SPV II as of June 30, 2025.
Item 5.
Ownership of 5 Percent or Less of a Class.
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The information in Item 4 is incorporated herein by reference.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Readout Capital, LP
Signature:
/s/ Matthew Smith
Name/Title:
Matthew Smith/Manager, Readout Capital GP, LLC, its General Partner
Date:
08/14/2025
Readout Capital GP, LLC
Signature:
/s/ Matthew Smith
Name/Title:
Matthew Smith/Manager
Date:
08/14/2025
ROC Holdings SPV II, LP
Signature:
/s/ Matthew Smith
Name/Title:
Matthew Smith/Manager, Readout Holdings GP, LLC, its General Partner
How many Precision BioSciences shares does Readout Capital beneficially own?
As of June 30, 2025 Readout Capital and Readout Capital GP each may be deemed to beneficially own 1,106,437 shares, representing 9.3% of the class.
What stake does Matthew Smith report in Precision BioSciences (symbol DTIL)?
Matthew Smith reported beneficial ownership of 1,119,311 shares, representing approximately 9.4% of the outstanding common stock as of June 30, 2025.
Does the filing disclose warrants that could increase ownership?
Yes. ROC Holdings SPV II directly held warrants exercisable for 220,000 shares, included in shared power calculations.
What voting power is reported for the Readout entities?
Readout Capital and Readout Capital GP reported sole voting power over 200,000 shares and shared voting power over 906,437 shares as of June 30, 2025.
Were the securities acquired to influence control of the issuer?
The filing includes a certification stating the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
